Substituted imidazole as bombesin receptor subtype-3 modulators
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Jun 5, 2012
Grant Date -
Jan 28, 2010
app pub date -
Oct 16, 2007
filing date -
Oct 20, 2006
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
Certain novel substituted imidazoles are ligands of the human bombesin receptor and, in particular, are selective ligands of the human bombesin receptor subtype-3 (BRS-3). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the modulation of BRS-3, such as obesity, and diabetes.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully